Clinical trial Recruiting at 1 site Phase 2 Interventional Ages 10 to 70

Using egg yolk powder to treat severe traumatic brain injury

Official title: Evaluation of Antisecretory Factor in Treatment of Severe Traumatic Brain Injury With Multimodal Monitoring

Run by Skane University Hospital · NCT04117672 · Data updated 2026-11-12

This study is testing if an egg yolk powder can help improve recovery for people with severe traumatic brain injuries when added to their regular treatment.

Quick facts

PhasePhase 2
Study typeInterventional
Ages10 Years to 70 Years
SexAll
Enrollment20 (estimated)
SponsorSkane University Hospital
Academic / other
Locations1 site (Lund)
StatusRecruiting
StartedMarch 10, 2020
Main results expectedDecember 31, 2026
Study endsJune 30, 2027
Registry record updatedJanuary 21, 2026
Trial IDNCT04117672 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are individuals with severe traumatic brain injury and a Glasgow Outcome Scale score of less than 9 upon admission.

Probably not a fit

Patients with known egg yolk allergies or those with fixed and dilated pupils after initial surgery may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of Salovum, an egg yolk powder enriched with antisecretory factor, in addition to standard care for patients with severe traumatic brain injury. Participants will be randomly assigned to receive either Salovum or a placebo egg yolk powder, and various parameters such as intracranial pressure, brain oxygen levels, and inflammatory markers will be monitored. The goal is to assess whether Salovum can reduce cerebral edema and improve patient outcomes compared to standard treatment alone.

Why it matters

Potential benefit: If successful, this treatment could significantly improve recovery outcomes for patients with severe traumatic brain injury.

How similar studies have gone: Preliminary results from similar studies have shown promise in reducing intracranial pressure and improving outcomes in traumatic brain injury.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

Severe traumatic brain injury, Glasgow Outcome Scale (GCS) \<9 at admission to NICU.

Clinical indication for insertion of intracranial pressure monitor, intracerebral oxygen pressure monitor and microdialysis catheter.

Consultation with relatives or consent from guardians.

Exclusion Criteria:

Known egg yolk allergy.

Unilateral or bilateral fixed and dilated pupil after initial operative intervention.

Where it's running

  • Skane University Hopsital
    Lund, Sweden
    Recruiting

Study contacts

  • Principal investigator: Peter Siesjö, MD, PhD — Skane University Hospital
  • Study coordinator: Peter Siesjö, MD, PhD
  • Email: peter.siesjo@med.lu.se
  • Phone: +4646171274

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.